Cumberland Pharmaceuticals Inc. (CPIX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-04) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2026-05-05) · 99.1 | 8-K (2025-05-06) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-03) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-04) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-05) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2026-05-05) · 99.1 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-04) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-05) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Equity | ||
| Valuation and Qualifying Accounts | — |
|
| Notes | ||
| Collaborative Agreements | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | — |
|
| Discontinued Operations | — |
|
| Earnings (loss) Per Share | — |
|
| Employee Benefit Plans | — |
|
| Employment Agreements | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets and Goodwill | — |
|
| Inventories | — |
|
| Inventories, Net | — |
|
| Leases | ||
| Loss Per Share | ||
| Manufacturing and Supply Agreements | — |
|
| Market Concentrations | — |
|
| Organization | — |
|
| Organization and Basis of Presentation | — |
|
| Other Current and Other Long-term Liabilities | — |
|
| Other Income | — |
|
| Pay Vs Performance Disclosure | ||
| Product Acquisitions and Return of Product Rights | — |
|
| Property and Equipment | — |
|
| Quarterly Financial Information (unaudited) | — |
|
| Revenues | ||
| Segment Reporting | — |
|
| Shareholders' Equity | — |
|
| Shareholders' Equity and Debt | — |
|
| Significant Accounting Policies | — |
|
| Stock-based Compensation Plans | — |
|
| Subsequent Event | — |
|
| Vibativ, Sancuso and Reditrex Products | — |
|